EYPT
Price
$8.80
Change
-$0.10 (-1.12%)
Updated
Jun 17, 04:59 PM (EDT)
Capitalization
606.23M
43 days until earnings call
INMB
Price
$6.87
Change
-$1.15 (-14.34%)
Updated
Jun 17 closing price
Capitalization
159.46M
42 days until earnings call
Interact to see
Advertisement

EYPT vs INMB

Header iconEYPT vs INMB Comparison
Open Charts EYPT vs INMBBanner chart's image
EyePoint Pharmaceuticals
Price$8.80
Change-$0.10 (-1.12%)
Volume$22.19K
Capitalization606.23M
INmune Bio
Price$6.87
Change-$1.15 (-14.34%)
Volume$1.75M
Capitalization159.46M
EYPT vs INMB Comparison Chart in %
Loading...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EYPT vs. INMB commentary
Jun 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EYPT is a Hold and INMB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 18, 2025
Stock price -- (EYPT: $8.81 vs. INMB: $6.87)
Brand notoriety: EYPT and INMB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EYPT: 111% vs. INMB: 477%
Market capitalization -- EYPT: $606.23M vs. INMB: $159.46M
EYPT [@Biotechnology] is valued at $606.23M. INMB’s [@Biotechnology] market capitalization is $159.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $342.74B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EYPT’s FA Score shows that 1 FA rating(s) are green whileINMB’s FA Score has 0 green FA rating(s).

  • EYPT’s FA Score: 1 green, 4 red.
  • INMB’s FA Score: 0 green, 5 red.
According to our system of comparison, EYPT is a better buy in the long-term than INMB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EYPT’s TA Score shows that 6 TA indicator(s) are bullish while INMB’s TA Score has 4 bullish TA indicator(s).

  • EYPT’s TA Score: 6 bullish, 4 bearish.
  • INMB’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, EYPT is a better buy in the short-term than INMB.

Price Growth

EYPT (@Biotechnology) experienced а -4.34% price change this week, while INMB (@Biotechnology) price change was -12.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.14%. For the same industry, the average monthly price growth was +8.92%, and the average quarterly price growth was +2.18%.

Reported Earning Dates

EYPT is expected to report earnings on Jul 30, 2025.

INMB is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (-4.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EYPT($606M) has a higher market cap than INMB($159M). INMB YTD gains are higher at: 47.109 vs. EYPT (19.463). INMB has higher annual earnings (EBITDA): -41.52M vs. EYPT (-144.55M). EYPT has more cash in the bank: 318M vs. INMB (19.3M). INMB has less debt than EYPT: INMB (347K) vs EYPT (24.1M). EYPT has higher revenues than INMB: EYPT (56M) vs INMB (50K).
EYPTINMBEYPT / INMB
Capitalization606M159M381%
EBITDA-144.55M-41.52M348%
Gain YTD19.46347.10941%
P/E RatioN/AN/A-
Revenue56M50K112,000%
Total Cash318M19.3M1,648%
Total Debt24.1M347K6,945%
FUNDAMENTALS RATINGS
EYPT vs INMB: Fundamental Ratings
EYPT
INMB
OUTLOOK RATING
1..100
289
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
9894
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
3742
P/E GROWTH RATING
1..100
16100
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EYPT's Valuation (60) in the Pharmaceuticals Major industry is in the same range as INMB (92) in the Biotechnology industry. This means that EYPT’s stock grew similarly to INMB’s over the last 12 months.

INMB's Profit vs Risk Rating (94) in the Biotechnology industry is in the same range as EYPT (98) in the Pharmaceuticals Major industry. This means that INMB’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as INMB (99) in the Biotechnology industry. This means that EYPT’s stock grew similarly to INMB’s over the last 12 months.

EYPT's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as INMB (42) in the Biotechnology industry. This means that EYPT’s stock grew similarly to INMB’s over the last 12 months.

EYPT's P/E Growth Rating (16) in the Pharmaceuticals Major industry is significantly better than the same rating for INMB (100) in the Biotechnology industry. This means that EYPT’s stock grew significantly faster than INMB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EYPTINMB
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 5 days ago
85%
Bullish Trend 7 days ago
84%
Declines
ODDS (%)
Bearish Trend 27 days ago
89%
Bearish Trend 5 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 1 day ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CIAOX47.41N/A
N/A
Capital Advisors Growth Investor
JNEMX22.14N/A
N/A
JPMorgan International Equity R6
MSECX10.92N/A
N/A
Morgan Stanley Inst International Eq C
HWTIX10.97N/A
N/A
Hotchkis & Wiley Intl Sm Cp Dvsfd Val I
GEACX18.15-0.61
-3.25%
GMO Resources I

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with LYRA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
-1.44%
LYRA - EYPT
58%
Loosely correlated
-0.09%
OCUL - EYPT
56%
Loosely correlated
+0.23%
ATHE - EYPT
54%
Loosely correlated
+0.34%
BEAM - EYPT
54%
Loosely correlated
-2.58%
CRSP - EYPT
53%
Loosely correlated
+0.53%
More